Jinghua Pharmaceutical Group Co., Ltd.

Shenzhen Stock Exchange 002349.SZ

Jinghua Pharmaceutical Group Co., Ltd. Revenue for the year ending December 31, 2023: USD 212.93 M

Jinghua Pharmaceutical Group Co., Ltd. Revenue is USD 212.93 M for the year ending December 31, 2023, a -6.59% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Jinghua Pharmaceutical Group Co., Ltd. Revenue for the year ending December 31, 2022 was USD 227.95 M, a 6.67% change year over year.
Jinghua Pharmaceutical Group Co., Ltd. Revenue for the year ending December 31, 2021 was USD 213.70 M, a 8.86% change year over year.
Jinghua Pharmaceutical Group Co., Ltd. Revenue for the year ending December 31, 2020 was USD 196.30 M, a 18.11% change year over year.
Jinghua Pharmaceutical Group Co., Ltd. Revenue for the year ending December 31, 2019 was USD 166.20 M, a -15.62% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shenzhen Stock Exchange: 002349.SZ

Jinghua Pharmaceutical Group Co., Ltd.

CEO	Mr. Yunzhong Zhou
IPO Date	Feb. 3, 2010
Location	China
Headquarters	No 2-02#, Xrd Between 3 Haibin Rd & 2 To
Employees	1,493
Sector	Health Care
Industries Pharmaceuticals Petrochemicals

Description

Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenylbutazone, Primidone, Phenobarbital, Fluorouracil, Propylthiouracil, Piroxicam, and Flucytosine APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. Jinghua Pharmaceutical Group Co., Ltd. was founded in 1957 and is based in Nantong, China.

Key trends

Past 5 years